The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis

被引：0
|
作者：
Kongju Wu
Ming Yi
Shuang Qin
Qian Chu
Xinhua Zheng
Kongming Wu
机构：
[1] Medical School of Pingdingshan University,Department of Clinical Medicine
[2] Huazhong University of Science and Technology,Department of Oncology, Tongji Hospital of Tongji Medical College
来源：
Experimental Hematology & Oncology | / 8卷
关键词：
Immunotherapy; PD-1; PD-L1; CTLA-4; Immune checkpoint inhibitor; Combination therapy; Meta-analysis; Systematic review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)
    Wu, Yingcheng
    Ju, Qianqian
    Jia, Keren
    Yu, Jingyan
    Shi, Hui
    Wu, Huiqun
    Jiang, Maorong
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (01) : 45 - 51
  • [12] Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
    Feng, Yuqian
    Jin, Huimin
    Guo, Kaibo
    Xiang, Yuying
    Zhang, Yiting
    Du, Wurong
    Shen, Minhe
    Ruan, Shanming
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [13] Combination of CTLA-4 and PD-1 blockers for treatment of cancer
    Rotte, Anand
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
  • [14] Combination of CTLA-4 and PD-1 blockers for treatment of cancer
    Anand Rotte
    Journal of Experimental & Clinical Cancer Research, 38
  • [15] Multiomic meta-analysis of differential response to PD-1 and CTLA-4 blockade in metastatic melanoma
    Huang, Amy Y.
    Vokes, Natalie
    Ricker, Cora
    Aprati, Tyler
    Robitschek, Emily
    Yang, Jiekun
    Ho, Li-Lun
    Galani, Kyriakitsa
    Burke, Kelly P.
    Tarantino, Giuseppe
    Chen, Jiajia
    Sharpe, Arlene H.
    Van Allen, Eliezer M.
    Kellis, Manolis
    Boland, Genevieve M.
    Liu, David
    CANCER RESEARCH, 2023, 83 (07)
  • [16] Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-analysis
    Mi, Ze
    Zhang, Yunshu
    Feng, Zhichao
    Liu, Jiahao
    Wu, Jianmin
    Tan, Hongpei
    Ma, Xiaoqian
    Liu, Zhenguo
    Rong, Pengfei
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2022, 50 (01) : 301 - 309
  • [17] A study on the efficacy and Safety Evaluation of a novel PD-1/CTLA-4 bispecific antibody
    Song, Qi
    Jiang, Meiling
    Pan, Xinrong
    Zhou, Guanyue
    Zhang, Xiaomeng
    IMMUNOBIOLOGY, 2024, 229 (06)
  • [18] Gastrointestinal, pancreatic, and hepatic toxicity profile of CTLA-4 immune checkpoint inhibitors alone and in combination with PD-1/PD-L1 inhibitors: A meta-analysis of clinical trials.
    Ali, Faisal
    Hussain, Maryam R.
    Deep, Aman
    Abu-Sbeih, Hamzah
    Alrifai, Taha
    Myint, Phyo Thazin
    Gong, Zimu
    Kozma, Kelley Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [19] The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis
    Nie, Run-Cong
    Zhao, Chong-Bang
    Xia, Xiao-Wei
    Luo, Ying-Shan
    Wu, Ting
    Zhou, Zhi-Wei
    Yuan, Shu-Qiang
    Wang, Yun
    Li, Yuan-Fang
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [20] Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
    De Velasco, Guillermo
    Je, Youjin
    Bosse, Dominick
    Awad, Mark M.
    Ott, Patrick A.
    Moreira, Raphael B.
    Schutz, Fabio
    Bellmunt, Joaquim
    Sonpavde, Guru P.
    Hodi, F. Stephen
    Choueiri, Toni K.
    CANCER IMMUNOLOGY RESEARCH, 2017, 5 (04) : 312 - 318
12345